Literature DB >> 17916308

[A survey of gastroprotective drugs: prescription-indication in hospitalized patients].

Alvaro Hermida Ameijeiras1, Belén Cabana González, Vicente Lorenzo Zúñiga.   

Abstract

Prescription rates of anti-ulcer drugs in hospitals and their spill-over to general practice have risen over the last few years, increasing pharmaceutical expenses. The aim of this study was to analyze gastroprotective drug prescription habits in our hospital by assessing both prevalence and adherence to approved indications. An observational study of prescription-indication was performed with 2 cross sections separated by 6 months to avoid selection bias. We found overprescription of gastroprotective drugs, mainly proton pump inhibitors for the prevention of non-steroidal antiinflammatory drug-induced ulcer (17.1%). Overall, 77.6% of prescriptions had no acceptable indication, despite the availability of a specific protocol produced by the Pharmacy and Therapeutics Committee in our center. There was a high prevalence of prescriptions for non-approved indications such as prophylaxis in patients administered corticosteroids without non-steroidal anti-inflammatory agents (25.7%). New programs to train clinicians and clinical managers in rational drug use are required.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17916308     DOI: 10.1157/13110449

Source DB:  PubMed          Journal:  Gac Sanit        ISSN: 0213-9111            Impact factor:   2.139


  2 in total

1.  Prescribing patterns and economic costs of proton pump inhibitors in Colombia.

Authors:  Jorge Machado-Alba; Alejandra Fernández; Juan Daniel Castrillón; Carlos Felipe Campo; Luis Felipe Echeverri; Andrés Gaviria; Manuel José Londoño; Sergio Andrés Ochoa; Joaquín Octavio Ruíz
Journal:  Colomb Med (Cali)       Date:  2013-03-30

2.  [Omeprazole for everybody?].

Authors:  Diego P Sánchez; José J Guillén; Alberto M Torres; Fernando I Sánchez
Journal:  Aten Primaria       Date:  2014-04-01       Impact factor: 1.137

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.